INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $74,845 | -38.8% | 2,367 | -21.0% | 0.00% | -50.0% |
Q2 2023 | $122,218 | +22.1% | 2,997 | +11.6% | 0.00% | 0.0% |
Q1 2023 | $100,107 | +36.9% | 2,686 | +28.1% | 0.00% | +100.0% |
Q4 2022 | $73,129 | -45.4% | 2,096 | -12.2% | 0.00% | -66.7% |
Q3 2022 | $134,000 | +8.9% | 2,386 | +0.8% | 0.00% | +50.0% |
Q2 2022 | $123,000 | -21.2% | 2,368 | +10.2% | 0.00% | 0.0% |
Q1 2022 | $156,000 | -24.3% | 2,148 | +23.2% | 0.00% | -33.3% |
Q4 2021 | $206,000 | -13.4% | 1,743 | -1.6% | 0.00% | -25.0% |
Q3 2021 | $238,000 | -19.9% | 1,772 | -3.4% | 0.00% | -20.0% |
Q2 2021 | $297,000 | -99.9% | 1,834 | -35.8% | 0.01% | +150.0% |
Q1 2021 | $229,208,000 | +1432450.0% | 2,856 | +861.6% | 0.00% | – |
Q4 2020 | $16,000 | +300.0% | 297 | -25.8% | 0.00% | – |
Q1 2020 | $4,000 | -69.2% | 400 | -55.6% | 0.00% | – |
Q4 2019 | $13,000 | +8.3% | 900 | 0.0% | 0.00% | – |
Q3 2019 | $12,000 | +100.0% | 900 | +125.0% | 0.00% | – |
Q2 2019 | $6,000 | -45.5% | 400 | 0.0% | 0.00% | -100.0% |
Q3 2018 | $11,000 | – | 400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |